Joining the CEPI network of vaccine makers in the Global South, the Serum Institute of India (SII) is a major step forward for global health preparedness.
By working together, we may improve our ability to respond quickly, nimbly, and fairly to future public health illness epidemics.
SII
The Goals and Investments of CEPI
To increase SII’s production capacity, a worldwide alliance known as CEPI is putting up to $30 million. In the event of an epidemic or pandemic, the goal is to facilitate the rapid manufacture and distribution of investigational vaccinations.
Rapid manufacture and fair distribution of inexpensive vaccinations to impacted communities will be made possible by this strategic investment, which will enable vaccine developers sponsored by CEPI to transfer their technology to SII within days or weeks of an outbreak.
CEPI’s One Hundred Day Objective
Working together, CEPI and SII are achieving the lofty 100 Days Mission, which has the support of the G7, the G20, and prominent figures in the business world.
Within three months of a pandemic danger being discovered, the mission’s goal is to produce new vaccines against both known and unknown infectious illnesses.
It is anticipated that SII’s integration into CEPI’s production network will be important in accomplishing this objective.
Aid for Top-Priority Infectious Agents
The money from CEPI will help SII improve its production capacity and will also go toward creating, storing, and licensing vaccines against the diseases that are most important to CEPI.
To better prepare for possible disease outbreaks, the two organizations are working together to determine which vaccinations have CEPI support and which SII would prioritize.
Joining the ranks of CEPI’s Global Manufacturing Network SII are three South African institutions: Aspen, Senegalese Institut Pasteur de Dakar, and Indonesian Bio Farma.
The Center for Excellence in Vaccine Innovation (CEPI) established this network to support vaccine manufacturers in the worldwide South and increase their worldwide reach.
Locations most threatened by lethal viruses like Lassa fever, nipah, disease X, and others that CEPI has designated as having epidemic or pandemic potential are the ones that receive the most attention.
Richard Hatchett, MD’s Point of View
Concerns about epidemics and pandemics are on the rise, and CEPI CEO Dr. Richard Hatchett has stressed the need of being increasingly prepared.
“Avoiding another Covid-like catastrophe in the future requires us to prepare to confront these threats head-on,” he said, “Living in an era of heightened epidemic and pandemic risk, evidenced by the increasing prevalence, speed, and spread of outbreaks of infectious disease.”
